RxDoctor Payments Data

Patrick Bennett, MD

Urology · Greenbrae, CANPI 1891713418

Payments from drug & device makers

$6,109in general payments, 2019–2025

Across 221 payments — averaging $27.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$956
  • AbbVie$796
  • Boston Scientific$414
  • Astellas Pharma US Inc$404
  • Rochester Medical Corporation$334
  • C. R. Bard, Inc. & Subsidiaries$257
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$6,00998%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,109 in reported general payments places this provider in the 65th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$442,104
Medicare patients
1,225
Services billed
3,604

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron47$35,439
GemtesaVibegron31$27,095
Tamsulosin Hcl233$4,164
Testosterone24$1,706
Potassium Citrate ErPotassium Citrate16$1,400
Finasteride104$1,235
NitrofurantoinNitrofurantoin Macrocrystal25$1,016
Trospium Chloride18$740
Oxybutynin Chloride ErOxybutynin Chloride18$636
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim68$613
Ciprofloxacin Hcl89$302
Bicalutamide13$197
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen30$184
Alfuzosin Hcl ErAlfuzosin Hcl14$138
Alprazolam45$79

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$404$35,43947 claims
Sumitomo Pharma America, Inc.Gemtesa$956$27,09531 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,324 urology providers in California.

Other urology in Greenbrae

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →